SLEEP ON Your SIDE (SOS) Study

Philips Clinical & Medical Affairs Global14 enrolled

Overview

Comparison of the NightBalance Sleep Position Trainer (SPT) to Positive Airway Pressure (PAP) for the Treatment of Positional Obstructive Sleep Apnea (POSA). Primary Objective: Efficacy and Adherence of the SPT over 3 months of use compared to PAP for the treatment of POSA. The study is run from centers in France, the UK and Germany.

Participants are randomly allocated to receive one of two treatments, either Automatic Positive Airway Pressure (APAP) or NightBalance Sleep Position Therapy for a three month period. Participants are sent home with instructions to use that device nightly at home for three months. After three months of using the first device, they return to the doctor for assessment of the efficacy of the device using a sleep test and the compliance read from the device. Upon conclusion of the first three month treatment period, patients receive the alternative treatment for a further three months. At the end of the second three month period, participants return to their doctor again to assess the efficacy of the last device and read the compliance. Before any treatment and after each treatment, patients undergo a sleep test and complete some questionnaires. During each treatment period, patients complete a healthcare utilization diary and report any problems.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Obstructive Sleep Apnea

Interventions

NightBalance Sleep Position Trainer (SPT)DEVICE

NightBalance Sleep Position Trainer (SPT) avoids POSA patients from sleeping on their back by delivering a vibrational stimulus, via a small device which is worn in a chest strap during sleep, each time the patient rolls to their back. This prompts the patient to roll over onto their side.

Automatic Positive Airway Pressure (APAP)DEVICE

Automatic Positive Airway Pressure (APAP) is a pump that provides a positive flow of air to keep the airway open.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subject is adult 2. Either: Treatment naïve, or PAP non-complier (defined as current AAP user with \<3 hours per night in the last 3 months per compliance download), and willing to use the APAP device per protocol 3. Diagnosis of POSA meeting all the following criteria per control PSG within 6 months of screening: AHI of \>15 during PSG with symptoms of sleepiness per Investigator discretion, or AHI of \>15 during respiratory polygraphy with comorbidities (e.g. atrial fibrillation, resistant hypertension, etc.) 4. Supine AHI at least twice the lateral AHI 5. Lateral AHI \<10 6. Supine time \>30% and \<70% 7. Understands the study protocol and is willing and able to comply with study requirements and sign informed consent. APAP non-compliant subjects must be willing to use their APAP device per protocol. Exclusion Criteria: 1. Prior or current therapy or treatment for OSA (for Treatment naïve group); Greater than an average of 3 hours per night of APAP use (in the APAP non-complier group) 2. A female of child-bearing potential that is pregnant or intends to become pregnant 3. Any unstable or severe medical condition of any organ system that at the discretion of the site Principal Investigator (PI) might affect the patient's participation in the study or generalization of treatment results 4. Taking medication that at the discretion of the site Principal Investigator (PI) might affect the patient's participation in the study or generalization of treatment results 5. Oxygen use 6. The presence of any other sleep disorder (central sleep apnea (CSA \>5), periodic limb movement disorder (PLMAI \>15), clinical diagnosis of insomnia or narcolepsy) 7. Excessive alcohol consumption (\>21 drinks/week) 8. The use of any illegal drug(s), per subject report 9. Night or rotating shift work 10. Severe claustrophobia 11. Shoulder, neck, or back complaints that restrict sleeping position 12. Subject requires use of more than 2 pillows under the head while sleeping or sleeps in a bed/chair with raised upper body position

Locations (18)

Centre Hospitalier Universitaire Angers

Angers, France

CHU Grenoble Alpes

Grenoble, France

Outcomes

Primary Outcomes

Change of Apnea-Hypopnea Index (AHI)

Efficacy will be measured as Change of Apnea-Hypopnea Index (AHI) from baseline to 3 months and from 3 months to 6 months (NightBalance SPT non-inferior to PAP)

Time frame: Baseline,3 months and 6 months

Difference of the total hours medical device use between each treatment arm

Adherence will be measured as the difference between the total hours medical device use from baseline to 3 months and from 3 months to 6 months (NightBalance SPT superior to PAP)

Time frame: 3 months and 6 months

Secondary Outcomes

Daytime Sleepiness

Daytime sleepiness is measured using Epworth Sleepiness Scale (ESS). Epworth Sleepiness Scale (ESS), has a minimum value 0, maximum value 24 with higher values indicate worsening daytime sleepiness.

Time frame: Baseline,3 months and 6 months

Impact of sleepiness on activities of daily living

Impact of sleepiness on activities of daily living is measured using Functional Outcomes of Sleep Questionnaire (FOSQ). The FOSQ is a sleep related quality of life is measured across five dimensions; activity level, vigilance, intimacy and sexual relationships, general productivity, social outcome. Each rate the difficulty of performing a given activity on a 4-point scale, min value 0, max value 4. Low scores indicate no difficulty, higher scores extreme difficulty.

Time frame: Baseline,3 months and 6 months

Health related quality of life

Health related quality of life is measured using EQ-5D at baseline and at the end of each 3 month treatment arm. Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems. Responses are coded as single-digit numbers. The digits for the five dimensions can be combined in a 5-digit code that describes the respondent's health state with lower scores indicting worsening health status and higher values improved health status.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.